

PUBLICATIONS 2022 BBE – Gustave Roussy

BUREAU DE BIOSTATISTIQUE ET D'EPIDEMIOLOGIE

BIOSTATISTICS AND EPIDEMIOLOGY DEPARTMENT

1. Sirab N, **Drubay D**, Maillé P, Popova T, Ngo C, Gentien D, Moktefi A, Soyeux-Porte P, Pelletier R, Reyes C, Henry E, Pouessel D, Vordos D, Lebret T, de Reyniès A, Paoletti X, Radvanyi F, Allory Y.
Multilayer spectrum of intratumoral heterogeneity in basal bladder cancer.
The Journal of Pathology. 2022 Jan;256(1):108-118. doi: 10.1002/path.5813.
Epub 2021 Nov 9. PMID : 34611919
2. Le Pechoux C, Pourel N, Barlesi F, Lerouge D, Antoni D, Lamezec B, Nestle U, DeMadelaine J, Pichon E, Larrouy A, Lavole A, Argo-Leignel D, Derollez M, Faivre-Finn C, Hatton MQ, Riesterer O, Bouvier-Morel E, **Dunant A**, Edwards JG, Thomas PA, Mercier O, **Bardet A**.
Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART): an open-label, randomised, phase 3 trial.
The Lancet Oncology. 2022 Jan;23(1):104-114.
doi: 10.1016/S1470-2045(21)00606-9. Epub 2021 Dec 15. PMID : 34919827
3. Martin M, **Hill C**, Bewley S, MacLennan AH, Brailon A.
Transgenerational adverse effects of valproate? A patient report from 90 affected families. Birth defects research . 2022 Jan 1;114(1):13-16.
doi: 10.1002/bdr2.1967. Epub 2021 Dec 5. PMID : 34866359
4. Dourthe ME, Phulpin A, **Auperin A**, Bosq J, Couec ML, Dartigues P, Ducassou S, Garnier N, Haouy S, Leblanc T, Leruste A, Paillard C, Rigaud C, Simonin M, Patte C, Minard-Colin V.
Rituximab in addition to LMB-based chemotherapy regimen in children and adolescents with primary mediastinal large B-cell lymphoma: results of the French LMB2001 prospective study. Haematologica.
2022 Sep 1;107(9):2173-2182. doi: 10.3324/haematol.2021.280257
PMID: 35236054

5. Vigouret-Viant L, **Legoupil C**, **Bardet A**, Laurent C, Ducreux M, Laurent S, Mateus C, Dauchy S, Blot F.
Development of a Decision-Aid Form (DAF) for the stratification of care in a French comprehensive cancer center, a tool to support identification of care goals. *Annals of Palliative Medicine*. 2022 Jun;11(6):1876-1887.
doi: 10.21037/apm-21-2854. Epub 2022 Feb 28. PMID : 35272472
6. Abbaci M, Conversano A, **Karimi M**, Mathieu MC, Rouffiac V, De Leeuw F, **Michiels S**, Laplace-Builhé C, Mazouni C.
Near-Infrared Fluorescence Axillary Reverse Mapping (ARM) Procedure in Invasive Breast Cancer: Relationship between Fluorescence Signal in ARM Lymph Nodes and Clinical Outcomes. *Cancers*. 2022 May 25;14(11):2614.
doi: 10.3390/cancers14112614. PMID: 35681595
7. Quivoron C, Tarabay A, Michot JM, **Paqès A**, Lecourt H, **Aupérin A**, Danu A, Lazarovici J, Rossignol J, Ghez D, Dartigues P, Vergé V, Massard C, Camara-Clayette V, Ribrag V, Sarkozy C.
Cell-free DNA sequencing as a potential screening tool for phase I targeted treatment in refractory/relapse diffuse large B cell lymphoma. *Haematologica*. 2022 Aug 1;107(8):1928-1932. doi: 10.3324/haematol.2021.280464.
PMID : 35320922
8. Burke GAA, Minard-Colin V, **Aupérin A**, Alexander S, Pillon M, Delgado R, Zsíros J, Uyttebroeck A, Dartigues P, Miles RR, Kazanowska B, Chiang AK, Haouy S, Bollard CM, Csoka M, Wheatley K, Barkauskas DA, Adamson PC, Vassal G, Patte C, Gross TG. Reply to R. Lakhotia et al.
Journal of Clinical Oncology. 2022 Jun 20;40(18):2064-2066.
doi: 10.1200/JCO.21.02912. Epub 2022 Apr 4. PMID : 35377710
9. Plais H, Labruyère M, Creutin T, Nay P, Plantefève G, Tapponnier R, Jonas M, Ngapmen NT, Le Guennec L, De Roquetaillade C, Argaud L, Jamme M, Goulenok C, Merouani K, Leclerc M, Sauneuf B, Shidasp S, Stoclin A, **Bardet A**, Mir O, **Ibrahimi N**, Llitjos JF.
Outcomes of Patients With Active Cancer and COVID-19 in the Intensive-Care Unit: A Multicenter Ambispective Study. *Frontiers in Oncology*. 2022 Mar 10;12:858276. doi: 10.3389/fonc.2022.858276. eCollection 2022.
PMID : 35359407

10. Charles C, **Bardet A**, **Larive A**, Gorwood P, Ramoz N, Thomas E, Viari A, Rousseau-Tsangaris M, Dumas A, Menvielle G, Everhard S, Martin AL, Gbenou SY, Havas J, El-Mouhebb M, Di Meglio A, André F, Pistilli B, Coutant C, Cottu P, Mérimèche A, Lerebours F, Tredan O, Vanlemmens L, Jouannaud C, Levy C, Vaz-Luis I, **Michiels S**, Dauchy S.
Characterization of Depressive Symptoms Trajectories After Breast Cancer Diagnosis in Women in France. JAMA Network Open.
2022 Apr 1;5(4):e225118. doi: 10.1001/jamanetworkopen.2022.5118.
PMID : 35420663
11. Chapuis N, **Ibrahimi N**, Belmondo T, Goulvestre C, Berger AE, Mariaggi AA, Andrieu M, Chenevier-Gobeaux C, **Bayle A**, Campos L, Cheurfa C, Chocron R, Diehl JL, Doumenc B, Duchemin J, Duprat M, François F, Gendron N, Mirault T, Pène F, Philippe A, Pommeret F, Sanchez O, Smadja DM, Szwebel TA, Silvin A, Ginhoux F, Lacroix L, Jules-Clément G, Rapeteramana S, Mavier C, Steller L, Perniconi B, André F, **Drubay D**, Fontenay M, Hüe S, Paul S, Solary E.
Dynamics of circulating calprotectin accurately predict the outcome of moderate COVID-19 patients. EBioMedicine. 2022 Jun;80:104077.
doi: 10.1016/j.ebiom.2022.104077. Epub 2022 May 26. PMID : 35644124
12. Lee RJ, Wysocki O, Zhou C, Shotton R, Tivey A, Lever L, Woodcock J, Albiges L, Angelakas A, Arnold D, Aung T, Banfill K, Baxter M, Barlesi F, Bayle A, Besse B, Bhogal T, Boyce H, Britton F, Calles A, Castelo-Branco L, Copson E, Croitoru AE, Dani SS, Dickens E, Eastlake L, Fitzpatrick P, **Foulon S**, Frederiksen H, Frost H, Ganatra S, Gennatas S, Glenthøj A, Gomes F, Graham DM, Hague C, Harrington K, Harrison M, Horsley L, Hoskins R, Huddar P, Hudson Z, Jakobsen LH, Joharatnam-Hogan N, Khan S, Khan UT, Khan K, Massard C, Maynard A, McKenzie H, Michielin O, Mosenthal AC, Obispo B, Patel R, Pentheroudakis G, Peters S, Rieger-Christ K, Robinson T, Rogado J, Romano E, Rowe M, Sekacheva M, Sheehan R, Stevenson J, Stockdale A, Thomas A, Turtle L, Viñal D, Weaver J, Williams S, Wilson C, Palmieri C, Landers D, Cooksley T; ESMO Co-Care, Dive C, Freitas A, Armstrong AC.
Establishment of CORONET, COVID-19 Risk in Oncology Evaluation Tool, to Identify Patients With Cancer at Low Versus High Risk of Severe Complications of COVID-19 Disease On Presentation to Hospital.
JCO Clinical Cancer Informatics. 2022 May;6:e2100177.
doi: 10.1200/CCI.21.00177. PMID : 35609228
13. de Kerangal Q, **Kapso R**, Morinière S, Laure B, **Bonastre J**, Moya-Plana A.
Sentinel lymph node biopsy versus selective neck dissection in patients with early oral squamous cell carcinoma: A cost analysis.
Journal of Stomatology, Oral and Maxillofacial Surgery.
2022 Jun;123(3):372-376. doi: 10.1016/j.jormas.2021.05.003.
Epub 2021 May 14. PMID : 34000437

14. Or Z, **Rococco E**, Touré M, **Bonastre J**.
Impact of Competition Versus Centralisation of Hospital Care on Process Quality: A Multilevel Analysis of Breast Cancer Surgery in France.
International Journal of Health Policy and Management.
2022 Apr 1;11(4):459-469. doi: 10.34172/ijhpm.2020.179. PMID : 33008262
15. Di Meglio A, Martin E, Crane TE, Charles C, Barbier A, Raynard B, **Mangin A**, Tredan O, Bouleuc C, Cottu PH, Vanlemmens L, Segura-Djezzar C, Lesur A, Pistilli B, Joly F, Ginsbourger T, Coquet B, Pauporte I, Jacob G, Sirven A, **Bonastre J**, Ligibel JA, **Michiels S**, Vaz-Luis I.
A phase III randomized trial of weight loss to reduce cancer-related fatigue among overweight and obese breast cancer patients: MEDEA Study design.
Trials. 2022 Mar 4;23(1):193. doi: 10.1186/s13063-022-06090-6.
PMID : 35246219
16. Leboulleux S, Bournaud C, Chougnet CN, Zerdoud S, Al Ghuzlan A, Catargi B, Do Cao C, Kelly A, Barge ML, Lacroix L, Dygai I, Vera P, Rusu D, Schneegans O, Benisvy D, Klein M, Roux J, Eberle MC, Bastie D, Nascimento C, Giraudet AL, Le Moullec N, Bardet S, Drui D, Roudaut N, Godbert Y, Morel O, Drutel A, Lamartina L, Schvartz C, Velayoudom FL, Schlumberger MJ, Leenhardt L, **Borget I**.
Thyroidectomy without Radioiodine in Patients with Low-Risk Thyroid Cancer.
The New England Journal of Medicine. 2022 Mar 10;386(10):923-932.
doi: 10.1056/NEJMoa2111953. PMID : 35263518
17. Lamartina L, Leboulleux S, **Borget I**, Schlumberger M.
Global thyroid estimates in 2020. The Lancet Diabetes & Endocrinology.
2022 Apr;10(4):235-236. doi: 10.1016/S2213-8587(22)00048-1.
Epub 2022 Mar 7. PMID : 35271820
18. Leboulleux S, Schlumberger MJ, **Borget I**.
Thyroidectomy without Radioiodine in Low-Risk Thyroid Cancer. Reply.
The New England Journal of Medicine. 2022 Jun 2;386(22):2155.
doi: 10.1056/NEJMc2204553. PMID : 35648717
19. Luyten J, Connolly MP, Verbeke E, Buhler K, Scotland G, Lispi M, Revelli A, **Borget I**, Cedrin-Durnerin I, D'Hooghe T.
Economic evaluation of Medically Assisted Reproduction: An educational overview of methods and applications for healthcare professionals.
2022 Dec;85(Pt B):217-228. doi: 10.1016/j.bpobgyn.2022.01.008.
Epub 2022 Feb 2. PMID : 35219590

20. Farah L, Magne N, Martelli N, Sotton S, Zerbib M, **Borget I**, Scher N, Guetta T, Chargari C, Bauduceau O, Toledano A.
Robot-Assisted Surgery vs Robotic Stereotactic Body Radiotherapy in Prostate Cancer: A Cost-Utility Analysis. *Frontiers in Oncology*. 2022 May 24;12:834023. doi: 10.3389/fonc.2022.834023. eCollection 2022. PMID : 35686090
21. Leboulleux S, **Borget I**, Schlumberger M.
Post-operative radioactive iodine administration in patients with low-risk thyroid cancer. *Nature Reviews Endocrinology*. 2022 Oct;18(10):585-586. doi: 10.1038/s41574-022-00709-z.. PMID : 35725924
22. Baciarello G, Delva R, Gravis G, Tazi Y, Beuzeboc P, Gross-Goupil M, Bompas E, Joly F, Greilsamer C, Hon TNT, Barthelemy P, Culine S, Berdah JF, Deblock M, Ratta R, Flechon A, Cheneau C, **Maillard A**, Martineau G, **Borget I**, Fizazi K; Groupe d'Etude des Tumeurs Uro-Genitales (GETUG).
Patient Preference Between Cabazitaxel and Docetaxel for First-line Chemotherapy in Metastatic Castration-resistant Prostate Cancer: The CABADOC Trial. *European Urology*. 2022 Mar;81(3):234-240. doi: 10.1016/j.eururo.2021.10.016. Epub 2021 Nov 14. PMID : 34789394
23. Gascon P, **Borget I**, Comet A, Carton L, Matonti F, Dupont-Benjamin L.
Costs comparison of treating diabetic macular edema with aflibercept, ranibizumab or dexamethasone at 1 year in France (INVICOST study). *European Journal of Ophthalmology*. 2022 May;32(3):1702-1709. doi: 10.1177/11206721211033480. Epub 2021 Jul 20. PMID : 34284605
24. **Grumberg V**, Chouaïd C, Cotté FE, Jouaneton B, Jolivel R, Gaudin AF, Reynaud D, Assié JB, **Borget I**.
Long-term hospital resource utilization and associated costs of care for patients initiating nivolumab in advanced non-small cell lung cancer in France. *Journal of medical economics*. Jan-Dec 2022;25(1):691-699. doi: 10.1080/13696998.2022.2079291. PMID : 35587018
25. Girault I, Adam J, Shen S, Roy S, **Brard C**, Faouzi S, Routier E, Lupu J, Warren S, Sorg K, Ong S, Morel P, Scoazec J-Y, Vagner S, Robert C.
A PD-1/PD-L1 Proximity Assay as a Theranostic Marker for PD-1 Blockade in Patients with Metastatic Melanoma. *Clinical Cancer Research*. 2022 Feb 1;28(3):518-525. doi: 10.1158/1078-0432.CCR-21-1229. Epub 2021 Nov 16. PMID : 34785583

26. Aupomerol M, **Chaltiel D**, Pautier P, Wehrer D, Véron L, Degousée L, Fasse L, Guérault-Accolas L, Di Meglio A, Scotté F, De-Jesus A, Vaz-Luis I, Delalogue S, Lambertini M, Pistilli B.
Breast Cancer Patients' Experience and Wishes Regarding Communication on Sexual Health: The BEROSE Study. *Cancer Investigation*.
2022 Jul;40(6):483-493. doi: 10.1080/07357907.2022.2066112.
Epub 2022 May 1. PMID : 35468006
27. **Chaltiel D**, Julia C, Chaltiel R, Baudry J, Touvier M, Deschamps V, Latino-Martel P, Fezeu L, Hercberg S, Kesse-Guyot E.
Prospective association between adherence to the 2017 French dietary guidelines and risk of death, CVD and cancer in the NutriNet-Santé cohort. *The British Journal of Nutrition*. 2022 Feb 28;127(4):619-629.
doi: 10.1017/S0007114521001367. Epub 2021 May 21.
PMID : 34016201
28. Bouaoud J, Temam S, Galmiche L, **Cozic N**, Bolle S, Belhous K, Kolb F, Qassemyar Q, Bidault F, Couloigner V, Picard A, Le Deley MC, Mahier-Ait Oukhatar C, Gaspar N, Kadlub N.
Head and neck Ewing sarcoma: French surgical practice analysis pleads for surgery centralization. *Journal of cranio-maxillofacial Surgery*.
2022 May;50(5):439-448. doi: 10.1016/j.jcms.2021.01.030. Epub 2021 Feb 6.
PMID : 35063337
29. Derosa L, Routy B, Thomas AM, Iebba V, Zalcman G, Friard S, Mazieres J, Audigier-Valette C, Moro-Sibilot D, Goldwasser F, Silva CAC, Terrisse S, Bonvalet M, Scherpereel A, Pegliasco H, Richard C, Ghiringhelli F, Elkrief A, Desilets A, Blanc-Durand F, Cumbo F, Blanco A, Boidot R, Chevrier S, Daillère R, Kroemer G, Alla L, Pons N, Le Chatelier E, Galleron N, Roume H, Dubuisson A, Bouchard N, Messaoudene M, **Drubay D**, Deutsch E, Barlesi F, Planchard D, Segata N, Martinez S, Zitvogel L, Soria JC, Besse B.
Intestinal *Akkermansia muciniphila* predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer. *Nature Medicine*.
2022 Feb;28(2):315-324. doi: 10.1038/s41591-021-01655-5. Epub 2022 Feb 3.
PMID : 35115705
30. Loi S, Salgado R, Adams S, Pruneri G, Francis PA, Lacroix-Triki M, Joensuu H, Dieci MV, Badve S, Demaria S, Gray R, Munzone E, **Drubay D**, Lemonnier J, Sotiriou C, Kellokumpu-Lehtinen PL, Vingiani A, Gray K, André F, Denkert C, Piccart M, Roblin E, **Michiels S**.
Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer. *NPJ Breast Cancer*. 2022 Jan 11;8(1):3.
doi: 10.1038/s41523-021-00362-1. PMID : 35017545

31. Marchais A, Marques da Costa ME, Job B, **Abbas R**, **Drubay D**, Piperno-Neumann S, Fromigué O, Gomez-Brouchet A, Redini F, Droit R, Lervat C, Entze-Werle N, Pacquement H, Devoldere C, Cupissol D, Bodet D, Gandemer V, Berger M, Marec-Berard P, Jimenez M, Vassal G, Geoerger B, Brugières L, Gaspar N.
Immune Infiltrate and Tumor Microenvironment Transcriptional Programs Stratify Pediatric Osteosarcoma into Prognostic Groups at Diagnosis. *Cancer Research*. 2022 Mar 15;82(6):974-985.
doi: 10.1158/0008-5472.CAN-20-4189. PMID : 35078815
32. Fahrner JE, Lahmar I, Goubet AG, Haddad Y, Carrier A, Mazzenga M, **Drubay D**, Alves Costa Silva C; Lyon COVID Study Group, de Sousa E, Thelemaque C, Melenotte C, Dubuisson A, Geraud A, Ferrere G, Birebent R, Bigenwald C, Picard M, Cerbone L, Lérias JR, Laparra A, Bernard-Tessier A, Kloeckner B, Gazzano M, Danlos FX, Terrisse S, Pizzato E, Flament C, Ly P, Tartour E, Benhamouda N, Meziani L, Ahmed-Belkacem A, Miyara M, Gorochov G, Barlesi F, Trubert A, Ungar B, Estrada Y, Pradon C, Gallois E, Pommeret F, Colomba E, Lavaud P, Deloger M, Droin N, Deutsch E, Gachot B, Spano JP, Merad M, Scotté F, Marabelle A, Griscelli F, Blay JY, Soria JC, Merad M, André F, Villemonteix J, Chevalier MF, Caillat-Zucman S, Fenollar F, Guttman-Yassky E, Launay O, Kroemer G, La Scola B, Maeurer M, Derosa L, Zitvogel L.
The Polarity and Specificity of Antiviral T Lymphocyte Responses Determine Susceptibility to SARS-CoV-2 Infection in Patients with Cancer and Healthy Individuals. *Cancer Discovery*. 2022 Apr 1;12(4):958-983.
doi: 10.1158/2159-8290.CD-21-1441. PMID : 35179201
33. Fizazi K, **Foulon S**, Carles J, Roubaud G, McDermott R, Fléchon A, Tombal B, Supiot S, Berthold D, Ronchin P, Kacso G, Gravis G, Calabro F, Berdah JF, Hasbini A, Silva M, Thiery-Vuillemin A, Latorzeff I, Mourey L, Laguerre B, Abadie-Lacourtoisie S, Martin E, El Kouri C, Escande A, Rosello A, Magne N, Schlurmann F, Priou F, Chand-Fouche ME, Freixa SV, Jamaluddin M, Rieger I, Bossi A; PEACE-1 investigators.
Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design. *The Lancet*. 2022 Apr 30;399(10336):1695-1707.
doi: 10.1016/S0140-6736(22)00367-1. Epub 2022 Apr 8.
PMID : 35405085

34. **Hill C**, Barouki R, Audouze K, Coumoul X.
[Endocrine disruptors : a discussed risk] [Article in French].
La Revue du Praticien. 2022 Jan;72(1):13-16. PMID: 35258248
35. Petrovic D, Bodinier B, Dagnino S, Whitaker M, **Karimi M**, Campanella G, Haugdahl Nøst T, Polidoro S, Palli D, Krogh V, Tumino R, Sacerdote C, Panico S, Lund E, Dugué PA, Giles GG, Severi G, Southey M, Vineis P, Stringhini S, Bochud M, Sandanger TM, Vermeulen RCH, Guida F, Chadeau-Hyam M. Epigenetic mechanisms of lung carcinogenesis involve differentially methylated CpG sites beyond those associated with smoking. European Journal of Epidemiology. 2022 Jun;37(6):629-640. doi: 10.1007/s10654-022-00877-2. Epub 2022 May 20. PMID : 35595947
36. **Early Breast Cancer Trialists' Collaborative Group (EBCTCG)**.
Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials. The Lancet Oncology. 2022 Mar;23(3):382-392. doi: 10.1016/S1470-2045(21)00758-0. Epub 2022 Feb 3. PMID : 35123662
37. Loriot Y, **Texier M**, Culine S, Fléchon A, Thiery-Vuillemin A, Gravis G, Geoffrois L, Chevreau C, Gross-Goupil M, Barthelemy P, Bompas E, Mahammedi H, Laguerre B, Lacourtoisie SA, Helissey C, Ladoire S, Abraham C, Massard C, Grimaldi S, Fizazi K. The GETUG SEMITEP Trial: De-escalating Chemotherapy in Good-prognosis Seminoma Based on Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography. European urology. 2022 Aug;82(2):172-179. doi: 10.1016/j.eururo.2022.04.031. Epub 2022 May 20. PMID : 35599187
38. Riudavets M, Naigeon M, **Texier M**, Dorta M, Barlesi F, Mazieres J, Varga A, Cassard L, Boselli L, Grivel J, NgoCamus M, Lacroix L, Mezquita L, Besse B, Chaput N, Planchard D.
Gefitinib plus tremelimumab combination in refractory non-small cell lung cancer patients harbouring EGFR mutations: The GEFTREM phase I trial. Lung Cancer. 2022 Apr; 166: 255-264. doi: 10.1016/j.eururo.2022.04.03. Epub 2021 Dec 3. PMID : 34953624

39. Baldini C, Danlos FX, Varga A, **Texier M**, Halse H, Mouraud S, Cassard L, Champiat S, Signolle N, Vuagnat P, Martin-Romano P, Michot JM, Bahleda R, Gazzah A, Boselli L, Bredel D, Grivel J, Mohamed-Djalim C, Escriou G, Grynszpan L, Bigorgne A, Rafie S, Abbassi A, Ribrag V, Postel-Vinay S, Hollebecque A, Susini S, Farhane S, Lacroix L, Parpaleix A, Laghouati S, Zitvogel L, Adam J, Chaput N, Soria JC, Massard C, Marabelle A.
Safety, recommended dose, efficacy and immune correlates for nintedanib in combination with pembrolizumab in patients with advanced cancers.
Journal of Experimental & Clinical Cancer Research. 2022 Jul 7;41(1):217.
doi: 10.1186/s13046-022-02423-0. PMID : 35794623
40. Doyen J, Besse B, **Texier M**, Bonnet N, Levy A.
PD-1 iNhibitor and chemotherapy with concurrent IRradiation at VARied tumor sites in advanced Non-small cell lung cAncer: the Prospective Randomized Phase 3 NIRVANA-Lung Trial. Clinical Lung Cancer. 2022 May; 23(3):e252-e256.doi: 10.1016/j.clc.2021.10.008. Epub 2021 Oct 24.
PMID : 34810130
41. Schenone L, Houillier C, **Tanguy ML**, Choquet S, Agbetiafa K, Ghesquières H, Damaj G, Schmitt A, Bouabdallah K, Ahle G, Gressin R, Cornillon J, Houot R, Marolleau JP, Fornecker LM, Chinot O, Peyrade F, Bouabdallah R, Moluçon-Chabrot C, Gyan E, Chauchet A, Casasnovas O, Oberic L, Delwail V, Abraham J, Roland V, Waultier-Rascalou A, Willems L, Morschhauser F, Fabbro M, Ursu R, Thieblemont C, Jardin F, Tempescul A, Malaise D, Touitou V, Nichelli L, Le Garff-Tavernier M, Plessier A, Bourget P, Bonmati C, Wantz-Mézières S, Giordan Q, Dorvaux V, Charron C, Jabeur W, Hoang-Xuan K, Taillandier L, Soussain C; French network for oculocerebral lymphoma (LOC network).
Intensive chemotherapy followed by autologous stem cell transplantation in primary central nervous system lymphomas (PCNSLs).
Therapeutic outcomes in real life-experience of the French Network.
Bone marrow transplantation. 2022 Jun;57(6):966-974.
doi: 10.1038/s41409-022-01648-z. Epub 2022 Apr 14. PMID: 35422077
42. **Pages A**, Costa N, Gonzalez-Bautista E, Mounie M, Juillard-Condât B, Molinier L, Cestac P, Rolland Y, Vellas Y, De Souto Barreto P, MAPT/DSA Group.
Screening for deficits on intrinsic capacity domains and associated healthcare costs. Archives of Gerontology and Geriatrics. 2022 May-Jun;100:104654.
doi: 10.1016/j.archger.2022.104654. Epub 2022 Feb 7. PMID : 35193041
43. Ayaden N, Sitbon P, **Pages A**, Tselikas L, Bourgain JL.
Pain after Interventional Radiology in Oncology: A Case-Control Study from a 5-Year Cohort. Cancers (Basel). 2022 May 24;14(11):2576.
doi: 10.3390/cancers14112576. PMID : 35681559

44. **Ollier E**, Blanchard P, **Le Teuff G**, **Michiels S**. Penalized Poisson model for network meta-analysis of individual patient time-to-event data. *Statistics in Medicine*. 2022 Jan 30;41(2):340-355. doi: 10.1002/sim.9240. Epub 2021 Oct 28. PMID: 34710951
45. **Abbas R**, Wason J, **Michiels S**, **Le Teuff G**. A two-stage drop-the-losers design for time-to-event outcome using a historical control arm. *Pharmaceutical statistics*. 2022 Jan;21(1):268-288. doi: 10.1002/pst.2168. Epub 2021 Sep 8. PMID: 34496117
46. Gregorich M, Melograna F, **Sunqvist M**, **Michiels S**, Van Steen K, Heinze G. Individual-specific networks for prediction modelling - A scoping review of methods. *BMC Medical Research Methodology*. 2022 Mar 6;22(1):62. doi: 10.1186/s12874-022-01544-6. PMID: 35249534
47. Berlanga P, Pierron G, Lacroix L, Chicard M, Adam de Beaumais T, Marchais A, Harttrampf AC, Iddir Y, **Larive A**, Soriano Fernandez A, Hezam I, **Chevassus C**, Bernard V, Cotteret S, Scoazec JY, Gauthier A, Abbou S, Corradini N, André N, Aerts I, Thebaud E, Casanova M, Owens C, Hladun-Alvaro R, **Michiels S**, Delattre O, Vassal G, Schleiermacher G, Geoerger B. The European MAPPYACTS Trial: Precision Medicine Program in Pediatric and Adolescent Patients with Recurrent Malignancies. *Cancer discovery*. 2022 May 2;12(5):1266-1281. doi: 10.1158/2159-8290.CD-21-1136. PMID : 35292802
48. Di Meglio A, Havas J, Gbenou AS, Martin E, El-Mouhebb M, Pistilli B, Menvielle G, Dumas A, Everhard S, Martin AL, Cottu PH, Lerebours F, Coutant C, Lesur A, Tredan O, Soulie P, Vanlemmens L, Joly F, Delalogue S, Ganz PA, André F, Partridge AH, Jones LW, **Michiels S**, Vaz-Luis I. Dynamics of Long-Term Patient-Reported Quality of Life and Health Behaviors After Adjuvant Breast Cancer Chemotherapy. *Journal of Clinical Oncology*. 2022 Sep 20;40(27):3190-3204. doi: 10.1200/JCO.21.00277. Epub 2022 Apr 21. PMID: 35446677
49. Vaz-Luis I, Di Meglio A, Havas J, El-Mouhebb M, Lapidari P, Presti D, Soldato D, Pistilli B, Dumas A, Menvielle G, Charles C, Everhard S, Martin AL, Cottu PH, Lerebours F, Coutant C, Dauchy S, Delalogue S, Lin NU, Ganz PA, Partridge AH, André F, **Michiels S**. Long-Term Longitudinal Patterns of Patient-Reported Fatigue After Breast Cancer: A Group-Based Trajectory Analysis. *Journal of Clinical Oncology*. 2022 Jul 1;40(19):2148-2162. doi: 10.1200/JCO.21.01958. Epub 2022 Mar 15. PMID: 35290073

50. Ligorio F, Di Cosimo S, Verderio P, Ciniselli CM, Pizzamiglio S, Castagnoli L, Dugo M, Galbardi B, Salgado R, Loi S, **Michiels S**, Triulzi T, Tagliabue E, El-Abed S, Izquierdo M, de Azambuja E, Nuciforo P, Huober J, Moscetti L, Janni W, Coccia-Portugal MA, Corsetto PA, Belfiore A, Lorenzini D, Daidone MG, Vingiani A, Gianni L, Pupa SM, Bianchini G, Pruneri G, Vernieri C.
Predictive role of CD36 expression in HER2-positive breast cancer patients receiving neoadjuvant trastuzumab. *Journal of the National Cancer Institute*. 2022 Dec 8;114(12):1720-1727. doi: 10.1093/jnci/djac126.
PMID : 35789270
51. Barlesi F, Tomasini P, **Karimi M**, **Michiels S**, Raimbourg J, Daniel C, Janicot H, Madroszyk A, Audigier-Valette C, Quoix E, Mazieres J, Moro-Sibilot D, Dansin E, Molinier O, Morel H, Pichon E, Cortot A, Otto J, Chomy FO, Souquet PJ, Cloarec N, Giroux Leprieur E, Bieche I, Lacroix L, Boyault S, Attignon V, Soubeyran I, Morel A, Tran-Dien A, Jacquet A, Dall'Olio FG, Jimenez M, Soria JC, Besse B.
Comprehensive genome profiling in patients with metastatic non-small cell lung cancer: the precision medicine phase 2 randomized SAFIR02-Lung trial. *Clinical Cancer Research*. 2022 Sep 15;28(18):4018-4026.
doi: 10.1158/1078-0432.CCR-22-0371. PMID : 35802649
52. Baker JL, Di Meglio A, Gbenou AS, El Mouhebb M, Iyengar NM, **Michiels S**, Cottu P, Lerebours F, Coutant C, Lesur A, Tredan O, Vanlemmens L, Jouannaud C, Hrab I, Everhard S, Martin AL, Arveux P, Fabrice A, Vaz-Luis I, Jones LW.
Association between physical activity and neoadjuvant chemotherapy completion and pathologic complete response in primary breast cancer: the CANTO study. *British journal of cancer*. 2022 Sep;127(5):886-891.
doi: 10.1038/s41416-022-01870-y. Epub 2022 Jun 17. PMID : 35715631
53. Nguyen Van Long F, Lardy-Cleaud A, Carène D, **Rossoni C**, Catez F, Rollet P, Pion N, Monchiet D, Dolbeau A, Martin M, Simioni V, Bray S, Le Beherec D, Mosele F, Bouakka I, Colombe-Vermorel A, Odeyer L, Diot A, Jordan LB, Thompson AM, Jamen F, Dubois T, Chabaud S, **Michiels S**, Treilleux I, Bourdon JC, Pérol D, Puisieux A, André F, Diaz JJ, Marcel V.
Low level of Fibrillarin, a ribosome biogenesis factor, is a new independent marker of poor outcome in breast cancer. *BioMed Central cancer*. 2022 May 11;22(1):526. doi: 10.1186/s12885-022-09552-x. PMID : 35545761
54. Martin E, Di Meglio A, Menvielle G, Arvis J, Bourmaud A, **Michiels S**, Pistilli B, Vaz-Luis I, Dumas A.
Informing the development of multidisciplinary interventions to help breast cancer patients return to work: a qualitative study. *Supportive care in cancer*. 2022 Oct;30(10):8287-8299. doi: 10.1007/s00520-022-07262-5.
Epub 2022 Jul 12. PMID : 35819520

55. Di Meglio A, Havas J, Soldato D, Presti D, Martin E, Pistilli B, Menvielle G, Dumas A, Charles C, Everhard S, Martin AL, Coutant C, Tarpin C, Vanlemmens L, Levy C, Rigal O, Delaloge S, Lin NU, Ganz PA, Partridge AH, André F, **Michiels S**, Vaz-Luis I.
Development and Validation of a Predictive Model of Severe Fatigue After Breast Cancer Diagnosis: Toward a Personalized Framework in Survivorship Care. *Journal of clinical oncology*. 2022 Apr 1;40(10):1111-1123.
doi: 10.1200/JCO.21.01252. Epub 2022 Jan 21. PMID : 35061509
56. Conversano A, Abbaci M, **Karimi M**, Mathieu MC, de Leeuw F, **Michiels S**, Laplace-Builhé C, Mazouni C.
Axillary reverse mapping using near-infrared fluorescence imaging in invasive breast cancer (ARMONIC study). *European Journal of Surgical Oncology*. 2022 Dec;48(12):2393-2400. doi: 10.1016/j.ejso.2022.07.004. Epub 2022 Jul 8. PMID : 35840448
57. de Jong VMT, Wang Y, Ter Hoeve ND, Opdam M, Stathonikos N, Józwiak K, Hauptmann M, Cornelissen S, Vreuls W, Rosenberg EH, Koop EA, Varga Z, van Deurzen CHM, Mooyaart AL, Córdoba A, Groen EJ, Bart J, Willems SM, Zolota V, Wesseling J, Sapino A, Chmielik E, Ryska A, Broeks A, Voogd AC, Loi S, **Michiels S**, Sonke GS, van der Wall E, Siesling S, van Diest PJ, Schmidt MK, Kok M, Dackus GMHE, Salgado R, Linn SC.
Prognostic Value of Stromal Tumor-Infiltrating Lymphocytes in Young, Node-Negative, Triple-Negative Breast Cancer Patients Who Did Not Receive (neo)Adjuvant Systemic Therapy. 2022 Jul 20;40(21):2361-2374.
doi: 10.1200/JCO.21.01536. Epub 2022 Mar 30. PMID : 35353548
58. Mogenet A, Barlesi F, Besse B, **Michiels S**, **Karimi M**, Tran-Dien A, Girard N, Mazieres J, Audigier-Valette C, Locatelli-Sanchez M, Kamal M, Gestraud P, Hamza A, Jacquet A, Jimenez M, Yara S, Greillier L, Bertucci F, Planchard D, Soria JC, Bieche I, Tomasini P.
Molecular profiling of non-small-cell lung cancer patients with or without brain metastases included in the randomized SAFIR02-LUNG trial and association with intracranial outcome. *Lung Cancer*. 2022 Jul;169:31-39.
doi: 10.1016/j.lungcan.2022.05.004. Epub 2022 May 18. PMID : 35609409
59. **Rincourt SL**, **Michiels S**, **Drubay D**.
Complex Disease Individual Molecular Characterization Using Infinite Sparse Graphical Independent Component Analysis. *Cancer Informatics*. 2022 Jul 15;21:11769351221105776.
doi: 10.1177/11769351221105776. eCollection 2022. PMID : 35860346

60. Pautier P, Italiano A, Piperno-Neumann S, Chevreau C, Penel N, Firmin N, Boudou-Rouquette P, Bertucci F, Balleyguier C, Lebrun-Ly V, Ray-Coquard I, Kalbacher E, **Bardet A**, Bompas E, Collard O, Isambert N, Guillemet C, Rios M, **Archambaud B**, Duffaud F; French Sarcoma Group. Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial. 2022 Aug;23(8):1044-1054. doi: 10.1016/S1470-2045(22)00380-1. Epub 2022 Jul 11. PMID : 35835135
61. De Ioris MA, Fabozzi F, Lodi M, Vitali G, De Pasquale MD, Del Baldo G, **Abbas R**, Agolini E, Crocoli A, Iacusso C, Milano GM, Serra A, Mastronuzzi A. The Fight Just Born-Neonatal Cancer: Rare Occurrence with a Favorable Outcome but Challenging Management. *Cancers*. 2022 Apr 29;14(9):2244. doi: 10.3390/cancers14092244. PMID : 35565372
62. Cerbone L, Nunno VD, Carril Ajuria L, Alves Costa Silva C, Colomba E, Guida A, **Salviat F**, Hirsch L, Benchimol-Zouari A, Flippot R, Escudier B, Albiges L. Activity of Systemic Treatments After Cabozantinib Failure in Advanced Metastatic Renal Cell Carcinoma. *Clinical Genitourinary Cancer*. 2022 Feb;20(1):80-87. doi: 10.1016/j.clgc.2021.09.001. Epub 2021 Sep 24. PMID: 34688544
63. Favier A, Boinon D, **Salviat F**, Mazouni C, De Korvin B, Tunon C, Salomon AV, Doutriaux-Dumoulin I, Vaysse C, Marchal F, Boulanger L, Chabbert-Buffet N, Zilberman S, Coutant C, Espié M, Cortet M, BouSSION V, Cohen M, Fermeaux V, Mathelin C, **Michiels S**, Delalogue S, Uzan C, Charles C. [Surgery or not on an atypical breast lesion? Taking anxiety into account in shared decision support from a prospective cohort of 300 patients]. [Article in French]. *Gynécologie, Obstétrique, Fertilité & Sénologie*. 2022 Feb;50(2):142-150. doi: 10.1016/j.gofs.2021.09.010. Epub 2021 Sep 22. PMID : 34562643
64. Chen J, Facchinetti F, Braye F, Yurchenko AA, Bigot L, Ponce S, Planchard D, Gazzah A, Nikolaev S, **Michiels S**, Vasseur D, Lacroix L, Tselikas L, Nobre C, Olaussen KA, Andre F, Scoazec JY, Barlesi F, Soria JC, Lorient Y, Besse B, Friboulet L. Single-cell DNA-seq depicts clonal evolution of multiple driver alterations in osimertinib-resistant patients. *Annals of oncology*. 2022 Apr;33(4):434-444. doi: 10.1016/j.annonc.2022.01.004. Epub 2022 Jan 21. PMID : 35066105

65. Kammer M, Dunkler D, **Michiels S**, Heinze G.
Evaluating methods for Lasso selective inference in biomedical research: a comparative simulation study. *BMC medical research methodology*.
2022 Jul 26;22(1):206. doi: 10.1186/s12874-022-01681-y. PMID : 35883041
66. Remon J, **Lacas B**, Herbst R, Reck M, Garon EB, Scagliotti GV, Ramlau R, Hanna N, Vansteenkiste J, Yoh K, Groen HJM, Heymach JV, Mandrekar SJ, Okamoto I, Neal JW, Heist RS, Planchard D, **Pignon JP**, Besse B; ANSELMA collaborative group.
ANtiangiogenic Second-line Lung cancer Meta-Analysis on individual patient data in non-small cell lung cancer: ANSELMA. *European Journal of Cancer*.
2022 May;166:112-125. doi: 10.1016/j.ejca.2022.02.002. Epub 2022 Mar 11.
PMID : 35286903
67. Witlox WJA, Ramaekers BLT, **Lacas B**, Le Pechoux C, Sun A, Wang SY, Hu C, Redman M, van der Noort V, Li N, Guckenberger M, van Tinteren H, Hendriks LEL, Groen HJM, Joore MA, De Ruyscher DKM.
Cost-effectiveness of prophylactic cranial irradiation in stage III non-small cell lung cancer. *Radiotherapy and oncology*. 2022 May;170:95-101.
doi: 10.1016/j.radonc.2022.02.036. Epub 2022 Mar 5. PMID : 35259416
68. Saghatchian M, **Lacas B**, Charles C, Ghouadni A, Clain GT, Boinon D, Delalogue S, Vaz-Luis I, Dauchy S, Amiel P.
BEAUTY and the breast: is adjuvant chemotherapy the right time for a beauty boost? Lessons learned from a large randomized controlled trial.
Quality of life research. 2022 Mar;31(3):723-732.
doi: 10.1007/s11136-021-02947-6. Epub 2021 Jul 29. PMID: 34324138
69. Goubet AG, Lordello L, Alves Costa Silva C, Peguillet I, Gazzano M, Mbogning-Fonkou MD, Thelemaque C, Lebacle C, Thibault C, Audenet F, Pignot G, Gravis G, Helissey C, Campedel L, Roupret M, Xylinas E, Ouzaid I, Dubuisson A, Mazzenga M, Flament C, Ly P, Marty V, Signolle N, Sauvat A, Sbarrato T, Filahi M, Davin C, Haddad G, Bou Khalil J, Bleriot C, Danlos FX, Dunsmore G, Mulder K, Silvin A, Raoult T, **Archambaud B**, **Belhechmi S**, Gomperts Boneca I, Cayet N, Moya-Nilges M, Mallet A, Daillere R, Rouleau E, Radulescu C, Allory Y, Fieschi J, Rouanne M, Ginhoux F, **Le Teuff G**, Derosa L, Marabelle A, VAN Dorp J, VAN Dijk N, van der Heijden MS, Besse B, Andre F, Merad M, Kroemer G, Scoazec JY, Zitvogel L, Loriot Y.
Escherichia coli-specific CXCL13-producing TFH are associated with clinical efficacy of neoadjuvant PD-1 blockade against muscle-invasive bladder cancer. *Cancer Discovery*. 2022 Oct 5;12(10):2280-2307.
doi: 10.1158/2159-8290.CD-22-0201. PMID : 35929803

70. Ribeiro AI, Fraga S, Severo M, Kelly-Irving M, Delpierre C, Stringhini S, Kivimaki M, Joost S, Guessous I, Severi G, Giles G, Sacerdote C, Vineis P, Barros H; **LIFEPATH Consortium**. Association of neighbourhood disadvantage and individual socioeconomic position with all-cause mortality: a longitudinal multicohort analysis. *Lancet Public Health*. 2022 May;7(5):e447-e457. doi: 10.1016/S2468-2667(22)00036-6. PMID : 35487230
71. Colomba E, Alves Costa Silva C, **Le Teuff G**, Elmawieh J, Afonso D, Benchimol-Zouari A, Guida A, Derosa L, Flippot R, Raynard B, Escudier B, Bidault F, Albiges L. Weight and skeletal muscle loss with cabozantinib in metastatic renal cell carcinoma. *Journal of Cachexia, Sarcopenia and Muscle*. 2022 Oct;13(5):2405-2416. doi: 10.1002/jcsm.13021. Epub 2022 Jul 28. PMID : 35903892
72. Del Baldo G, **Abbas R**, De Ioris MA, Di Ruscio V, Alessi I, Miele E, Mastronuzzi A, Milano GM. The Prognostic Role of the C-Reactive Protein and Serum Lactate Dehydrogenase in a Pediatric Series of Bone Ewing Sarcoma. *Cancers*. 2022 Jun 22;14(13):3064. doi: 10.3390/cancers14133064. PMID : 35804835
73. Abbaci M, Casiraghi O, Vergez S, **Maillard A**, Lakhdar AB, De Leeuw F, Crestani S, Ngo C, Koscielny S, Ferchiou M, Assouly N, Temam S, Laplace-Builhé C, Breuskin I. Diagnostic accuracy of in vivo early tumor imaging from probe-based confocal laser endomicroscopy versus histologic examination in head and neck squamous cell carcinoma. *Clinical oral investigations*. 2022 Feb;26(2):1823-1833. doi: 10.1007/s00784-021-04156-4. Epub 2021 Oct 12. PMID : 34636941
74. Wysocki O, Zhou C, Rogado J, Huddar P, Shotton R, Tivey A, Albiges L, Angelakas A, Arnold D, Aung T, Banfill K, Baxter M, Barlesi F, Bayle A, Besse B, Bhogal T, Boyce H, Britton F, Calles A, Castelo-Branco L, Copson E, Croitoru A, Dani SS, Dickens E, Eastlake L, Fitzpatrick P, **Foulon S**, Frederiksen H, Ganatra S, Gennatas S, Glenthøj A, Gomes F, Graham DM, Hague C, Harrington K, Harrison M, Horsley L, Hoskins R, Hudson Z, Jakobsen LH, Joharatnam-Hogan N, Khan S, Khan UT, Khan K, Lewis A, Massard C, Maynard A, McKenzie H, Michielin O, Mosenthal AC, Obispo B, Palmieri C, Patel R, Pentheroudakis G, Peters S, Rieger-Christ K, Robinson T, Romano E, Rowe M, Sekacheva M, Sheehan R, Stockdale A, Thomas A, Turtle L, Viñal D, Weaver J, Williams S, Wilson C, Dive C, Landers D, Cooksley T, Freitas A, Armstrong AC, Lee RJ, On Behalf Of The Esmo Co-Care. An International Comparison of Presentation, Outcomes and CORONET Predictive Score Performance in Patients with Cancer Presenting with COVID-19 across Different Pandemic Waves. *Cancers*. 2022 Aug 16;14(16):3931. doi: 10.3390/cancers14163931. PMID : 36010932

75. Hescot S, Al Ghuzlan A, Henry T, Sheikh Alard H, Lamartina L, **Borget I**, Hadoux J, Baudin E, Dupuy C, Nikitski AV, Nikiforov YE, Schlumberger M, Nikiforova MN, Leboulleux S.
Prognostic of recurrence and survival in poorly differentiated thyroid cancer. *Endocrine-related Cancer*. 2022 Sep 30;29(11):625-634.
doi: 10.1530/ERC-22-0151. Print 2022 Nov 1. PMID : 36040800
76. Palmer S, **Borget I**, Friede T, Husereau D, Karnon J, Kearns B, Medin E, Peterse EFP, Klijn SL, Verburg-Baltussen EJM, Fenwick E, Borrill J.
A Guide to Selecting Flexible Survival Models to Inform Economic Evaluations of Cancer Immunotherapies. *Value in Health*. 2022 Aug 13;S1098-3015(22)02105-2. doi: 10.1016/j.jval.2022.07.009. Online ahead of print.
PMID : 35970706
77. Nauwelaers I, Laudus N, Peeters D, Acs B, Denkert C, **Michiels S**, Horlings H, Siziopikou KP, Ely S, Zardavas D, Mustimbo R, Bartlett J, Floris G, Hartman J, van Deurzen CHM, Ceusters D, Dequeker E, Salgado R.
External Quality Assessment 2.0: The Importance of a Standardized Implementation of TILs for Daily and Trial Practices. *Cancers*.
2022 Aug 2;14(15):3762. doi: 10.3390/cancers14153762. PMID : 35954426
78. Kfoury M, Najean M, Lappara A, Voisin AL, Champiat S, Michot JM, Laghouati S, Robert C, Besse B, Soria JC, Lambotte O, Massard C, Marabelle A, **Texier M**.
Analysis of the association between prospectively collected immune-related adverse events and survival in patients with solid tumor treated with immune-checkpoint blockers, taking into account immortal-time bias.
Cancer Treatment Reviews. 2022 Aug 10;110:102452.
doi: 10.1016/j.ctrv.2022.102452. Online ahead of print. PMID : PMID: 35998515
79. **Pagès A**, Costa N, Mounié M, Cestac P, De Souto Barreto P, Rolland Y, Vellas B, Molinier L, Juillard-Condât B; MAPT/DSA Group.
Healthcare Costs Associated with Potentially Inappropriate Medication Prescribing Detected by Computer Algorithm Among Older Patients.
Drugs Aging. 2022 May;39(5):367-375. doi: 10.1007/s40266-022-00938-x.
Epub 2022 May 24. PMID : 35606646
80. **Deneche I**, Touzani R, Bouhnik AD, Rey D, Bendiane MK, Chirpaz E.
Factors associated with mammography screening among Reunionese women : a cross-sectional study. *Revue d'Epidémiologie et de Santé Publique*.
2022 Jun;70(3):117-122. doi: 10.1016/j.respe.2022.03.122. Epub 2022 Apr 28.
PMID: 35491336

81. Di Meglio A, Charles C, Martin E, Havas J, Gbenou A, Flaysakier JD, Martin AL, Everhard S, Laas E, Chopin N, Vanlemmens L, Jouannaud C, Levy C, Rigal O, Fournier M, Soulie P, Scotte F, Pistilli B, Dumas A, Menvielle G, André F, **Michiels S**, Dauchy S, Vaz-Luis I.
Uptake of Recommendations for Posttreatment Cancer-Related Fatigue Among Breast Cancer Survivors.
Journal of the National Comprehensive Cancer Network. 2022 Feb 7;1-13.
doi: 10.6004/jnccn.2021.7051. Online ahead of print. PMID: 35130491
82. Pautier P, **Tanguy ML**, **Archambaud B**.
Doxorubicin plus trabectedin for metastatic or unresectable leiomyosarcoma - Authors' reply. The Lancet Oncology. 2022 Oct;23(10):e445.
doi: 10.1016/S1470-2045(22)00563-0. PMID: 36174626
83. Palafox M, Monserrat L, Bellet M, Villacampa G, Gonzalez-Perez A, Oliveira M, Brasó-Maristany F, **Ibrahimi N**, Kannan S, Mina L, Herrera-Abreu MT, Òdena A, Sánchez-Guixé M, Capelán M, Azaro A, Bruna A, Rodríguez O, Guzmán M, Grueso J, Viaplana C, Hernández J, Su F, Lin K, Clarke RB, Caldas C, Arribas J, **Michiels S**, García-Sanz A, Turner NC, Prat A, Nuciforo P, Dienstmann R, Verma CS, Lopez-Bigas N, Scaltriti M, Arnedos M, Saura C, Serra V.
High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer. Nature communications.
2022 Sep 7;13(1):5258. doi: 10.1038/s41467-022-32828-6. PMID: 36071033
84. Le Corroller AG, **Bonastre J**.
Patient-reported measures: how useful in health economics?
The European Journal of Health Economics. 2022 Nov 8.
doi: 10.1007/s10198-022-01524-z. Online ahead of print. PMID : 36346476
85. **Kandel M**, **Bardet A**, Dalle S, Allayous C, Mortier L, Guillot B, Dutriaux C, Leccia MT, Dalac S, Montaudie H, Saiag P, Legoupil D, Brunet-Possenti F, Arnault JP, Quatrebarbes J, Beylot-Barry M, Maubec E, Lesimple T, Aubin F, Grob JJ, Granel-Brocard F, Stoebner PE, Dupuy A, Dreno B, **Michiels S**, Lebbe C, **Borget I**.
Cost-Effectiveness Analysis of Sequential Treatment Strategies for Advanced Melanoma in Real Life in France. Current oncology.
2022 Nov 27;29(12):9255-9270. doi: 10.3390/curroncol29120725.
PMID: 36547139
86. **Hilmi M**, Naoun N, Boilève A, Géraud A, **Bayle A**, Pagès A, Aupomerol M, Rouanne M, Madec FX, Pommeret F, Massard C, Baldini C, Scotté F, Champiat S. Evaluation of supportive care needs, sexuality and quality of life in phase 1 trials: a prospective monocentric study. Supportive care in cancer.
2022 Dec;30(12):9841-9849. doi: 10.1007/s00520-022-07407-6.
Epub 2022 Oct 22. PMID: 36271944

87. de Pouvourville G, Armoiry X, Lavorel A, Bilbault P, Maugendre P, Bensimon L, Beziz D, Blin P, **Borget I**, Bouée S, Collignon C, Dervaux B, Durand-Zaleski I, Julien M, de Léotoing L, Majed L, Martelli N, Séjourné T, Viprey M.
Données et preuves en vie réelle dans l'évaluation des technologies de santé : dans quels cas sont-elles complémentaires, substitutives, ou les seules sources de données par rapport aux essais cliniques ? [Article in French] *Thérapie*. 2022 Oct 29;S0040-5957(22)00236-0. doi: 10.1016/j.therap.2022.10.067. Online ahead of print. PMID: 36446648
88. Borson-Chazot, F, **Borget, I**, Mathonnet, M, Leenhardt, L.
SFE-AFCE-SFMN 2022 consensus on the management of thyroid nodules: Epidemiology and challenges in the management of thyroid nodules. *Annales d'endocrinologie (Paris)*. 2022 Dec;83(6):378-379. doi: 10.1016/j.ando.2022.10.003. Epub 2022 Oct 23. PMID: 36283463
89. de Pouvourville G, Armoiry X, Lavorel A, Bilbault P, Maugendre P, Bensimon L, Beziz D, Blin P, **Borget I**, Bouée S, Collignon C, Dervaux B, Durand-Zaleski I, Julien M, de Léotoing L, Majed L, Martelli N, Séjourné T, Viprey M.
Real-world data and evidence in health technology assessment: When are they complementary, substitutes, or the only sources of data compared to clinical trials? *Thérapie*. 2022 Nov 12;S0040-5957(22)00240-2. doi: 10.1016/j.therap.2022.11.001. Online ahead of print. PMID: 36464522
90. Palafox M, Monserrat L, Bellet M, Villacampa G, Gonzalez-Perez A, Oliveira M, Brasó-Maristany F, **Ibrahimi N**, Kannan S, Mina L, Herrera-Abreu MT, Òdena A, Sánchez-Guixé M, Capelán M, Azaro A, Bruna A, Rodríguez O, Guzmán M, Grueso J, Viaplana C, Hernández J, Su F, Lin K, Clarke RB, Caldas C, Arribas J, **Michiels S**, García-Sanz A, Turner NC, Prat A, Nuciforo P, Dienstmann R, Verma CS, Lopez-Bigas N, Scaltriti M, Arnedos M, Saura C, Serra V.
Author Correction: High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer. *Nature communications*. 2022 Nov 14;13(1):6928. doi: 10.1038/s41467-022-34580-3. PMID: 36376284
91. Colomba E, Alexandre J, **Le Teuff G**, Genestie C, Coupeuz D, Coquard IR, Brachet PE, de Percin S, Sajous C, Fabbro M, Delanoy N, Joly F, Frenel JS, Pautier P, Leary A.
Response to first line platinum-based chemotherapy in mismatch repair deficient (MMRd)/ microsatellite instability high (MSI-high) endometrial carcinoma. *Gynecologic oncology*. 2022 Dec 13;169:78-84. doi: 10.1016/j.ygyno.2022.11.029. Online ahead of print. PMID: 36521352

92. **Rincourt SL, Michiels S, Drubay D.**
A non-parametric Bayesian joint model for latent individual molecular profiles and survival in oncology. *Journal of Bioinformatics and Computational Biology*. 2022 Oct;20(5):2250022. doi: 10.1142/S0219720022500226. Epub 2022 Oct 27. PMID: 36287465
93. Rassy E, **Bardet A**, Bougacha O, Gantzer L, Lekens B, Delalogue S, André F, **Michiels S**, Pistilli B.
Association of Adherence to Endocrine Therapy Among Patients With Breast Cancer and Potential Drug-Drug Interactions. *JAMA network open*. 2022 Dec 1;5(12):e2244849. doi: 10.1001/jamanetworkopen.2022.44849. PMID: 36459136
94. Marmouset V, Decroocq J, Garciaz S, Etienne G, Belhabri A, Bertoli S, Gastaud L, Simand C, Chantepie S, Uzunov M, Genthon A, Berthon C, Chiche E, Dumas PY, Vargaftig J, Salmeron G, Lemasle E, Tavernier E, Delage J, Loirat M, Morineau N, Blanc-Durand F, Pautier P, Vergé V, Auger N, Thomas M, Stefani L, Lepelley M, Boyer T, Thepot S, Gourin MP, Bourquard P, Duchmann M, Morice PM, Michallet M, Adès L, Fenaux P, Récher C, Dombret H, **Pagès A**, Marzac C, Leary A, Micol JB; UNIHEM, French Network of Pharmacovigilance Centers, ALFA, FILO, and GFM.
Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience. *Clinical Cancer Research*. 2022 Dec 1;28(23):5211-5220. doi: 10.1158/1078-0432.CCR-22-1622. PMID: 36201165
95. Fasse L, Roche N, Flahault C, Garrouste-Orgeas M, Ximenes M, **Pages A**, Evin A, Dauchy S, Scotte F, Le Provost JB, Blot F, Mateus C.
The APSY-SED study: protocol of an observational, longitudinal, mixed methods and multicenter study exploring the psychological adjustment of relatives and healthcare providers of patients with cancer with continuous deep sedation until death. *BMC palliative care*. 2022 Dec 5;21(1):217. doi: 10.1186/s12904-022-01106-z. PMID: 36464684
96. Doyen J, Besse B, **Texier M**, Bonnet N, Levy A.
PD-1 iNhibitor and chemotherapy with concurrent IRradiation at VARied tumor sites in advanced Non-small cell lung cAncer: the Prospective Randomized Phase 3 NIRVANA-Lung Trial. *Clinical Lung Cancer*. 2022 May;23(3):e252-e256. doi: 10.1016/j.clcc.2021.10.008. Epub 2021 Oct 24. PMID: 34810130

97. Tran BT, Gelin A, Durand S, **Texier M**, Daste A, Toullec C, Benihoud K, Breuskin I, Gorphe P, Garic F, Brenner C, Le Tourneau C, Fayette J, Niki T, David M, Busson P, Even C.
Plasma galectins and metabolites in advanced head and neck carcinomas: evidence of distinct immune characteristics linked to hypopharyngeal tumors. *Oncoimmunology*. 2022 Dec 17;12(1):2150472.
doi: 10.1080/2162402X.2022.2150472. eCollection 2023. PMID: 36545254
98. Del Baldo G, Carai A, **Abbas R**, Cacchione A, Vinci M, Di Ruscio V, Colafati GS, Rossi S, Diomedi Camassei F, Maestro N, Temelso S, Pericoli G, De Billy E, Giovannoni I, Carboni A, Rinelli M, Agolini E, Mackay A, Jones C, Chiesa S, Balducci M, Locatelli F, Mastronuzzi A.
Targeted therapy for pediatric diffuse intrinsic pontine glioma: a single-center experience. *Therapeutic Advances in Medical Oncology*.
2022 Sep 6;14:17588359221113693. doi: 10.1177/17588359221113693.
eCollection 2022. PMID: 36090803
99. Rigault E, **Lacas B**, Glehen O, Smith D, Dupont-Bierre E, Guimbaud R, Malka D, Boige V, Fuerea A, **Pignon JP**, Ducreux M.
Intra-arterial hepatic bevacizumab and systemic chemotherapy in hepatic metastasis of colorectal cancer: A phase II multicentric trial in second-line treatment. *Cancer treatment and research communications*.
2022 Dec 16;34:100674. doi: 10.1016/j.ctarc.2022.100674.
Online ahead of print. PMID: 36565566
100. Tonon F, Di Bella S, **Giudici F**, Zerbato V, Segat L, Koncan R, Misin A, Toffoli B, D'Agaro P, Luzzati R, Fabris B, Bernardi S.
Discriminatory Value of Adiponectin to Leptin Ratio for COVID-19 Pneumonia. *International Journal of Endocrinology*. 2022 Apr 26;2022:9908450.
doi: 10.1155/2022/9908450. eCollection 2022. PMID: 35529082
101. Bramuzzo M, Grazian F, Grigoletto V, Daidone A, Martelossi S, Mario F, Maurel E, Lega S, **Giudici F**, Di Leo G, Barbi E.
Dietary Beliefs in Children and Adolescents with Inflammatory Bowel Disease and their Parents. *Journal of Pediatric Gastroenterology and Nutrition*.
2022 Sep 1;75(3):e43-e48. doi: 10.1097/MPG.0000000000003527.
Epub 2022 Jun 16. PMID: 35706104
102. **Deneche I**, Zoughailech D, Chirpaz E.
Socioeconomic inequalities in breast cancer survival in Reunion Island: The contribution of stage at diagnosis as a mediator. *Cancer Epidemiology*.
2022 Oct;80:102249. doi: 10.1016/j.canep.2022.102249. Epub 2022 Sep 5.
PMID: 36067573

103. Antonaglia C, Vidoni G, Contardo L, **Giudici F**, Salton F, Ruaro B, Confalonieri, Caneva M.
Low Arousal Threshold Estimation Predicts Failure of Mandibular Advancement Devices in Obstructive Sleep Apnea Syndrome. *Diagnostics (Basel)*. 2022 Oct 20;12(10):2548. doi: 10.3390/diagnostics12102548. PMID: 36292237
104. D'Angelo A, **Giudici F**, Chapman R, Darlow J, Kilihi H, Sobhani N, Cinelli M, Cappelletti MR, Strina C, Milani M, Generali D.
Clinico-Immunological Effects of a Single-Agent CDK4/6 Inhibitor in Advanced HR+/HER2- Breast Cancer Based on a Window of Opportunity Study. *Current issues in molecular biology*. 2022 Sep 15;44(9):4255-4267. doi: 10.3390/cimb44090292. PMID: 36135204
105. Paoletti X, **Michiels S**.
16e Conférence francophone d'Epidémiologie Clinique 29^e Journées des statisticiens des Centres de Lutte contre le Cancer Paris, 18-20 mai 2022. *Revue d'Epidémiologie et de Santé Publique*. 2022 May;70:S61-S62. 10.1016/j.respe.2022.04.001.
106. **Benkirane H**, Vakalopoulou M, Christodoulidis S, Garberis I-J, **Michiels S**, Cournède P-H.
Hyper-AdaC: Adaptive clustering-based hypergraph representation of whole slide images for survival analysis. *Proceedings of the 2nd Machine Learning for Health symposium. Proceedings of Machine Learning Research*. 2022 nov;193:405-418
107. **Hill C**.
[A propos de l'article "Is early-onset cancer an emerging global epidemic ?" : pas de panique !]. *Innovations & Thérapeutiques en Oncologie*. 2022 sept-oct ; vol 8 – n°5. doi : 10.1684/ito.2022.337